Charles Schwab’s Tonix Pharmaceuticals TNXP Stock Holding History

Charles Schwab’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$671K	Buy	52,613 +22,823	+77%	+$295K	﹤0.01%	3142
2026 Q1	$410K	Sell	29,790 -3,614	-11%	-$55.6K	﹤0.01%	3169
2025 Q4	$522K	Buy	33,404 +6,615	+25%	+$122K	﹤0.01%	3151
2025 Q3	$647K	Buy	26,789 +5,057	+23%	+$188K	﹤0.01%	3087
2025 Q2	$782K	Buy	+21,732	New	+$569K	﹤0.01%	2980
2022 Q2	–	Sell	-2	Closed	-$288K	–	3641
2022 Q1	$288K	Hold	2	–	–	﹤0.01%	3223
2021 Q4	$390K	Buy	2 +1	+100%	+$318K	﹤0.01%	3228
2021 Q3	$531K	Hold	1	–	–	﹤0.01%	3127
2021 Q2	$909K	Buy	+1	New	+$735K	﹤0.01%	2968
2021 Q1	–	Hold	0	–	–	–	3342
2020 Q4	–	Hold	0	–	–	–	3344
2020 Q3	–	Hold	0	–	–	–	3259

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Charles Schwab's TNXP Position: Q2 2026 in Review

Charles Schwab increased its Tonix Pharmaceuticals (TNXP) stake by 77% in Q2 2026, buying an estimated $295K and bringing the position to 52,613 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

Charles Schwab first reported a position in TNXP in Q2 2021 and has held it in 9 quarters since. The position peaked at $909K in Q2 2021. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Charles Schwab held 52,613 shares of Tonix Pharmaceuticals worth $671K as of Q2 2026.
Charles Schwab bought 22,823 Tonix Pharmaceuticals shares in Q2 2026, an estimated $295K.
Tonix Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3142 holding.
Charles Schwab first reported a position in Tonix Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
Charles Schwab's Tonix Pharmaceuticals position peaked at $909K in Q2 2021.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.